World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Kenneth Hallock Biography and Net Worth

Director of Greenwich LifeSciences

Mr. Hallock has over 40 years of experience in general management and new venture start-ups. He is currently a senior manager and partner in a private start-up equipment manufacturing company and has been in these roles for over 10 years. Mr. Hallock has worked in large industrial corporations such as NL Industries, Inc. and Anderson, Clayton, and Co., which were subsequently acquired. Mr. Hallock received a BSE in Chemical Engineering from Princeton University, and an MBA from Harvard Business School.

How do I contact Kenneth Hallock?: The corporate mailing address for Mr. Hallock and other Greenwich LifeSciences executives is , , . Greenwich LifeSciences can also be reached via phone at 832-819-3232 and via email at [email protected]. Learn More on Kenneth Hallock's contact information.
Has Kenneth Hallock been buying or selling shares of Greenwich LifeSciences?: Kenneth Hallock has not been actively trading shares of Greenwich LifeSciences during the past quarter. Most recently, on Friday, January 21st, Kenneth Hallock bought 300 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $16.32 per share, with a total value of $4,896.00. Learn More on Kenneth Hallock's trading history.
Who are Greenwich LifeSciences' active insiders?: Greenwich LifeSciences' insider roster includes Frank Daugherty (Insider), Kenneth Hallock (Director), David McWilliams (Director), Snehal Patel (CEO), and Jaye Thompson (VP). Learn More on Greenwich LifeSciences' active insiders.
Are insiders buying or selling shares of Greenwich LifeSciences?: During the last year, Greenwich LifeSciences insiders bought shares 21 times. They purchased a total of 53,400 shares worth more than $604,290.50. The most recent insider tranaction occured on April, 1st when CEO Snehal Patel bought 3,000 shares worth more than $57,240.00. Insiders at Greenwich LifeSciences own 52.9% of the company. Learn More about insider trades at Greenwich LifeSciences.
Information on this page was last updated on 4/1/2024.

Kenneth Hallock Insider Trading History at Greenwich LifeSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2022	Buy	300	$16.32	$4,896.00

Kenneth Hallock Buying and Selling Activity at Greenwich LifeSciences

Greenwich LifeSciences Company Overview

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Today's Range

Now: $12.34

$12.05

$12.91

50 Day Range

MA: $15.50

$11.24

$20.32

2 Week Range

Now: $12.34

$7.58

$21.44

Volume

30,894 shs

Average Volume

45,534 shs

Market Capitalization

$158.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38